Acupuncture as a Treatment Journey for Hypermobile Ehlers-Danlos Syndrome
Summary
The article uses the clichéd question of "journey vs. destination" as a framing device, likely to discuss the experience of living with hypermobile Ehlers-Danlos Syndrome (hEDS) and the role of acupuncture in managing symptoms. The content appears to be a personal or reflective piece exploring chronic illness management, the value of treatment processes versus outcomes, and how acupuncture fits into the hEDS patient experience.
Source
bskyAcupuncture as a Treatment Journey for Hypermobile Ehlers-Danlos Syndromebuff.lyKey quotes
· 3 pulledWhat's more important, the journey or the destination?
In theory, the best part is the journey, or the process of learning and growing and experiencing.
Sometimes the destination is what matters and how you get there means a lot less than your much-needed arrival.
You might also wanna read
A Linguist's Struggle to Articulate Chronic Illness Symptoms
The article explores the challenges faced by a linguist and chronic illness patient in articulating and measuring internal health sensations
thesicktimes.org·11mo ago
Personal Reflection on Using Proprietary Medical Devices for Diabetes Management
The article discusses the author's personal experience with diabetes and their difficult choice to use a proprietary continuous glucose moni
sfconservancy.org·6mo ago
Personalized health tech promises fall short for chronic condition patients
This article is a personal narrative from a Verge senior reviewer discussing the gap between the promises of personalized health technology
The Verge·1mo agoBeyond ACEs: When Trauma-Informed Care Misses Neurodivergent Children
Meet the expert: Dr. Ashley Liew on Intellectual Disabilities
Network meta-analysis finds conservative treatments for chronic low back pain lack long-term benefits
This article presents a network meta-analysis of conservative treatments for chronic non-specific low back pain, examining their effectivene
bmjmedicine.bmj.com·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.